Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause White blood cell count increased? 219 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 219 reports of White blood cell count increased have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 0.3% of all adverse event reports for OMALIZUMAB.

219
Reports of White blood cell count increased with OMALIZUMAB
0.3%
of all OMALIZUMAB reports
5
Deaths
141
Hospitalizations

How Dangerous Is White blood cell count increased From OMALIZUMAB?

Of the 219 reports, 5 (2.3%) resulted in death, 141 (64.4%) required hospitalization, and 4 (1.8%) were considered life-threatening.

Is White blood cell count increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 219 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause White blood cell count increased?

CLOZAPINE (2,988) ADALIMUMAB (1,710) RUXOLITINIB (1,529) IBRUTINIB (1,390) RITUXIMAB (886) METHOTREXATE (741) PREDNISONE (716) ETANERCEPT (615) IMATINIB (520) TOCILIZUMAB (478)

Which OMALIZUMAB Alternatives Have Lower White blood cell count increased Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All White blood cell count increased Reports All Drugs Causing White blood cell count increased OMALIZUMAB Demographics